Transforming Lives. Redefining Possibilities.
Everything we do at Actelion Pharmaceuticals Deutschland GmbH is focused on three things: putting patients first, being a great place to work, and living our shared values.
At Actelion Pharmaceuticals Deutschland GmbH , our purpose is to innovate to transform the lives of patients and their families.
We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
We have a diverse portfolio of marketed medicines including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience.
Actelion Pharmaceuticals Deutschland GmbH is a global, diversified Pharmaceutical CDMO and biotechnology company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health. manufacture of drugs that treat rare and orphan diseases. Some of the drugs it has produced have been used to treat patients with symptoms related to central nervous system disorders, irregular heart conditions, immune system disorders, and cancer. One of the focuses of Actelion is treating individuals with pulmonary arterial hypertension (PAH), a heart condition that leaves patients with a short life expectancy (7–9 years) even with treatment.scientists were among the first to work in the field of endothelin receptor antagonists. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
We manufacture and market a broad range of branded and generic pharmaceuticals, and over-the-counter (OTC) products directly or indirectly in more than 90 countries and regions, including the United States, us, Europe, the Middle East, Africa, Asia Pacific and Latin America.
As a part of the renowned Group, the Contract Development and Manufacturing Organisation (CDMO) division offers comprehensive biopharmaceutical services. They specialize in the development and manufacturing of biologics, including monoclonal antibodies, recombinant proteins, and biosimilars. With a global presence and cutting-edge facilities, they provide end-to-end solutions from cell line development to commercial manufacturing.
We have a diversified portfolio of products, which you can learn more about here.
The company established in December 1997, headquartered in Allschwil near Basel, Switzerland. The company is partnering Johnson & Johnson Innovative Medicine business segment.